The potential antidepressant-like effect of imidazoline I 2 ligand 2-BFI in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 37, Issue 1, 2012, Pages 15-21

  Tonello, Raquel ^a   Villarinho, Jardel Gomes ^a   da Silva Sant'Anna, Gabriela ^a   Tamiozzo, Lídia ^a   Machado, Pablo ^a   Trevisan, Gabriela ^a   Pinto Martins, Marcos Antônio ^a   Ferreira, Juliano ^a   Rubin, Maribel Antonello ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

2 BFI; Depression; I 2 imidazoline site; Monoamine oxidase A; Tail suspension test

Indexed keywords

2 (2 BENZOFURANYL) 2 IMIDAZOLINE; DIAZEPAM; IMIDAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; FORCED SWIMMING TEST; MALE; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; ROTAROD TEST; TRANQUILIZING ACTIVITY;

AFFINITY LABELS; ANIMALS; ANTIDEPRESSIVE AGENTS; BENZOFURANS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; IMMOBILIZATION; LIGANDS; MALE; MICE; TREATMENT OUTCOME;

EID: 84857781820     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.11.005     Document Type: Article

References (64)

1. 3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes. Naunyn Schmiedebergs Arch Pharmacol 1997, 356:39-47.
2. Anderson N.J., Seif I., Nutt D.J., Hudson A.L., Robinson E.S.J. Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. J Neurochem 2006, 96:1551-1559.
3. Archer J. Tests for emotionality in rats and mice: a review. Anim Behav 1973, 21:205-235.
4. Aricioglu F., Altunbas H. Is agmatine an endogenous anxiolytic/antidepressant agent?. Ann N Y Acad Sci 2003, 1009:136-140.
5. Bernstein H.G., Stich C., Jäger K., Dobrowolny H., Wick M., Steiner J. Agmatinase, an inactivator of the putative endogenous antidepressant agmatine, is strongly upregulated in hippocampal interneurons of subjects with mood disorders. Neuropharmacology 2012, 62:237-246.
6. Bourin M., Chenu F., Ripoll N., David D.J. A proposal of decision tree to screen putative antidepressants using forced swim and tail suspension tests. Behav Brain Res 2005, 164:266-269.
7. Bousquet P., Feldman J., Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984, 230:232-236.
8. Carpéné C., Collon P., Remaury A., Cordi A., Hudson A., Nutt D. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites. J Pharmacol Exp Ther 1995, 272:681-688.
9. Cervo L., Grignaschi G., Samanin R. Alpha 2-adrenoceptor blockade prevents the effect of desipramine in the forced swimming test. Eur J Pharmacol 1990, 175:301-307.
10. Chan S.L., Brown C.A., Scarpello K.E., Morgan N.G. The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1- and I2-sites. Br J Pharmacol 1994, 112:1065-1070.
11. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245.
12. Cryan J.F., Mombereau C., Vassout A. The tail suspension test for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005, 29:571-625.
13. De Angelis L. Experimental anxiety and antidepressant drugs: the effects of moclobemide, a selective reversible MAO-A inhibitor, fluoxetine and imipramine in mice. Naunyn Schmiedebergs Arch Pharmacol 1996, 354:379-383.
14. De Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996, 57(Suppl. 4):19-25.
15. Detke M.J., Wieland S., Lucki I. Blockade of the antidepressant-like effects of 8 OHDPAT, buspirone and desipramine in the rat forced swim test by 5HT1A receptor antagonists. Psychopharmacology (Berl) 1995, 119:47-54.
16. Duarte F.S., Lach G., Martins P.R.C., Romeiro G.A., Lima T.C.M. Evidence for the involvement of the monoaminergic system in the antidepressant-like action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a, d] cycloheptane in mice evaluated in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:368-374.
17. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54:597-606.
18. Eglen R.M., Hudson A.L., Kendall D.A., Nutt D.J., Morgan N.J., Wilson W.G., et al. Seeing through a glass darkly: casting light on imidazoline "I" sites. Trends Pharmacol Sci 1998, 19:381-390.
19. Elhwuegi A.S. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:435-451.
20. Eroǧlu L., Güven O. The effects of moclobemide on the yohimbine-induced anxiogenic action in the elevated plus-maze. Pharmacol Res 1998, 37:137-143.
21. Finn D.P., Martí O., Harbuz M.S., Vallès A., Belda X., Márquez C., et al. Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl) 2003, 167:195-202.
22. García-Sevilla J.A., Escribá P.V., Sastre M., Walzer C., Busquets X., Jaquet G., et al. Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims. Arch Gen Psychiatry 1996, 53:803-810.
23. García-Sevilla J.A., Escribá P.V., Walzer C., Bouras C., Guimon J. Imidazoline receptor proteins in brains of patients with Alzheimer's disease. Neurosci Lett 1998, 247:95-98.
24. García-Sevilla J.A., Escribá P.V., Ozaita A., La Harpe R., Walzer C., Eytan A., et al. Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem 1999, 72:282-291.
25. Godoy M.C., Fighera M.R., Souza F.R., Flores A.E., Rubin M.A., Oliveira M.R., et al. Alpha 2-adrenoceptors and 5-HT receptors mediate the antinociceptive effect of new pyrazolines, but not of dipyrone. Eur J Pharmacol 2004, 496:93-97.
26. Haddjeri N., Blier P., de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995, 4:11-17.
27. Holt A. Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?. J Psychiatry Neurosci 2003, 28:409-414.
28. Jones T.Z., Giurato L., Guccione S., Ramsay R.R. Interactions of imidazoline ligands with the active site of purified monoamine oxidase A. FEBS J 2007, 274:1567-1575.
29. Lalies M.D., Hibell A., Hudson A.L., Nutt D.J. Inhibition of central monoamine oxidase by imidazoline 2 site selective ligands. Ann N Y Acad Sci 1999, 881:114-117.
30. Lammers C.H., Diaz J., Schwartz J.C., Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 2000, 5:378-388.
31. Lanni C., Govoni S., Lucchelli A., Cinzia B. Depression and antidepressants: molecular and cellular aspect. Cell Mol Life Sci 2009, 66:2985-3008.
32. Lione L.A., Nutt D.J., Hudson A.L. [3H]-2-(2-benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors. Eur J Pharmacol 1996, 304:221-229.
33. 3H]2-(2-benzofuranyl)-2-imidazoline binding in the rat brain: a selective ligand for imidazoline I2 receptors. Eur J Pharmacol 1998, 353:123-135.
34. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987, 92:180-185.
35. Lladó J., Esteban S., Garcfa-Sevilla J.A. The α2-adrenoceptor antagonist idazoxan is an agonist at 5-HT1A autoreceptors modulating serotonin synthesis in the rat brain in vivo. Neurosci Lett 1996, 218:111-114.
36. Machado D.G., Kaster M.P., Binfaré R.W., Dias M., Santos A.R.S., Pizzolatti M.G., et al. Antidepressant-like effect of the extract from leaves of Schinus molle L. in mice: evidence for the involvement of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:421-428.
37. Maj J., Dziedzicka-Wasylewska M., Rogoz R., Rogoz Z., Skuza G. Antidepressant drugs given repeatedly change the binding of the dopamine D2 receptor agonist, [3H]N-0437, to dopamine D2 receptors in the rat brain. Eur J Pharmacol 1996, 304:49-54.
38. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K., Gray N.A., et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003, 53:707-742.
39. Michel M., Insel P. Are there multiple imidazoline binding sites?. Trends Pharmacol Sci 1989, 10:342-344.
40. Millan M.J. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur J Pharmacol 2004, 500:371-384.
41. Naderi N., Haghparast A., Saber-Tehrani A., Rezaii N., Alizadeh A.M., Khani A., et al. Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol Biochem Behav 2008, 89:64-75.
42. Neumeister A., Willeit M., Praschak-Rieder N., Asenbaum S., Stastny J., Hilger E., et al. Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol Med 2001, 31:1467-1473.
43. Nutt D.J., French N., Handley S., Hudson A., Husbands S., Jackson H., et al. Functional studies of specific imidazoline-2 receptor ligands. Ann N Y Acad Sci 1995, 763:125-139.
44. O'Neill M.F., Osborne D.J., Woodhouse S.M., Conway M.W. Selective imidazoline I2 ligands do not show antidepressant-like activity in the forced swim test in mice. J Psychopharmacol 2001, 15:18-22.
45. Piletz J.E., Halaris A., Nelson J., Qu Y., Bari M. Platelet I1-imidazoline binding sites are elevated in depression but not generalized anxiety disorder. J Psychiatr Res 1996, 30:147-168.
46. Piletz J.E., Baker R., Halaris A. Platelet imidazoline receptors as state marker of depressive symptomatology. J Psychiatr Res 2008, 42:41-49.
47. Pitchot W., Hansenne M., Pinto E., Reggers J., Fuchs S., Ansseau M. 5-Hydroxytryptamine 1A receptors, major depression, and suicidal behavior. Biol Psychiatry 2005, 58:854-858.
48. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
49. Raasch W., Muhle H., Dominiak P. Modulation of MAO activity by imidazoline and guanidine derivatives. Ann N Y Acad Sci 1999, 881:313-331.
50. Raddatz R., Parini A., Lanier S.M. Localization of the imidazoline binding domain on monoamine oxidase B. Mol Pharmacol 1997, 52:549-553.
51. Regunathan S., Reis D.J. Imidazoline receptors and their endogenous ligands. Annu Rev Pharmacol Toxicol 1996, 36:511-544.
52. Rénéric J.P., Bouvard M., Stinus L. Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test. Neuropsychopharmacology 2001, 24:379-390.
53. Rogoz R., Dziedzicka-Wasylevska M. Effects of antidepressant drugs on dopamine D2/D3 receptors in the rat brain differentiated by agonist and antagonist binding - an autoradiographic analysis. Naunyn Schmiedebergs Arch Pharmacol 1999, 359:178-186.
54. Rosel P., Arranz B., San L., Vallejo J., Crespo J.M., Urretavizcaya M., et al. Altered 5-HT (2A) binding sites and second messenger inositol trisphosphate (IP(3)) levels in hippocampus but not in frontal cortex from depressed suicide victims. Psychiatry Res 2000, 99:173-181.
55. Sant'Anna G.S., Machado P., Sauzem P.D., Rosa F.A., Rubin M.A., Ferreira J., et al. Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett 2009, 19:546-549.
56. Sastre-Colla A., Estebana S., Mirallesa A., Zanettia R., García-Sevilla J.A. The imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline is a dopamine-releasing agent in the rat striatum in vivo. Neurosci Lett 2001, 301:29-32.
57. Shah B.H., Saeed S.A., Rashid F., Gilani A.H. Dopamine potentiation of calcium ionophore, A 23187-induced platelet aggregation. Adv Exp Med Biol 1997, 407:537-540.
58. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
59. Svenningsson P., Chergui K., Rachleff I., Flajolet M., Zhang X., El Yacoubi M., et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006, 311:77-80.
60. Taksande B.G., Kotagale N.R., Tripathi S.J., Ugale R.R., Chopde C.T. Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacology 2009, 57:415-424.
61. Tesson F., Prip-Buus C., Lemoine A., Pegorier J.P., Parini A. Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. Major localization to the mitochondrial outer membrane. J Biol Chem 1991, 266:155-160.
62. Wiest S.A., Steinberg M.I. Binding of [3H]-2-(2-benzofuranyl)-2-imidazoline (BFI) to human brain: potentiation by tranylcypromine. Life Sci 1997, 60:605-615.
63. Zomkowski A.D., Hammes L., Lin J., Calixto J.B., Santos A.R., Rodrigues A.L. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 2002, 13:387-391.
64. Zomkowski A.D.E., Rosa A.O., Lin J., Santos A.R.S., Calixto J.B., Rodrigues A.L.S. Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res 2004, 1023:253-263.